脾氨肽辅助抗结核药物治疗肺结核的临床疗效观察.

Objective: To observe the clinical curative effect of anti-tuberculosis drugs assisted with spleen aminopeptide on tuber- culosis. Methods: According to random number table method, 120 patients with tuberculosis admitted to the hospital were divided into observation group and control group between June 2016 and June 2021. The control group was treated with routine anti-tuberculosis drugs, while observation group was additionally treated with spleen aminopeptide. The changes of lung lesions and cavities in both groups were evaluated. The negative conversion ratios of sputum culture after 2, 4 and 6 months of treatment, peripheral blood T lympho- cyte subsets (CD3+, CD4+, CD4+ /CD8+ ratio) before and after treatment in both groups were detected. Results: The total response rates of lung lesions and lung cavities in observation group were 95.00% and 93.33%, significantly higher than those in control group (83.33%, 80.00%) (P<0.05). After 6 months of treatment, difference in negative conversion ratio of sputum culture between the two groups was not statistically significant (P>0.05). After 2 and 4 months of treatment, negative conversion ratios of sputum culture in observation group were significantly higher than those in control group (P<0.05). The difference in CD3+, CD4+ and CD4+ /CD8+ ratio between the two groups before treatment, as well as those in control group before and after treatment was not significantly different ( P>0.05). After treat- ment, CD3+, CD4+ and CD4+ /CD8 + ratio in observation group were significantly increased, significantly higher than those in control group (P<0.05). Conclusions: The anti-tuberculosis drugs assisted with spleen aminopeptide are beneficial to improve clinical curative effect on tuberculosis, which may be related to enhancing immune function. And it is worthy of further clinical research. [ABSTRACT FROM AUTHOR]